Find Information About:

Drugs & Supplements

Get information and reviews on prescription drugs, over-the-counter medications, vitamins, and supplements. Search by name or medical condition.

Pill Identifier

Pill Identifier

Having trouble identifying your pills?

Enter the shape, color, or imprint of your prescription or OTC drug. Our pill identification tool will display pictures that you can compare to your pill.

Get Started

My Medicine

Save your medicine, check interactions, sign up for FDA alerts, create family profiles and more.

Get Started

WebMD Health Experts and Community

Talk to health experts and other people like you in WebMD's Communities. It's a safe forum where you can create or participate in support groups and discussions about health topics that interest you.

  • Second Opinion

    Second Opinion

    Read expert perspectives on popular health topics.

  • Community


    Connect with people like you, and get expert guidance on living a healthy life.

Got a health question? Get answers provided by leading organizations, doctors, and experts.

Get Answers

Sign up to receive WebMD's award-winning content delivered to your inbox.

Sign Up

Heart Failure Health Center

Font Size

Heart Failure: All ARBs Aren’t the Same

Study Suggests Higher Death Risk in Losartan Patients
WebMD Health News
Reviewed by Laura J. Martin, MD

Jan. 11, 2011 -- Blood pressure drugs in the class known as angiotensin II receptor blockers (ARBs) reduce mortality in patients with heart failure, but new research suggests that not all work equally well.

Heart failure patients in Sweden who took the drug candesartan (Atacand) had a lower risk of death than patients who took the drug losartan (Cozaar).

The analysis included more than 30,000 patients enrolled in a Swedish heart failure registry.

At one year, 90% of patients taking candesartan were still alive, compared to 83% of patients taking losartan. After five years, 61% of candesartan patients and 44% of losartan patients were living.

The study appears Jan. 12 in the Journal of the American Medical Association.

No ARB Class Effect

The naturally occurring hormone angiotensin II causes blood vessel walls to constrict and narrow, leading to an increase in blood pressure. ARBs lower blood pressure by blocking the action of angiotensin II.

Although the drugs have never been compared head to head for the treatment of heart failure, there have been suggestions that some ARBs are more effective than others.

In a 2007 study involving patients who were 65 and older, survival rates among patients taking losartan were worse than rates for patients taking other ARBs, including candesartan, irbesartan (Avepro), and valsartan (Diovan).

The findings suggested that the benefits derived by heart failure patients were not due to an ARB class effect.

The newly published study raises more questions about a class effect, but they do not mean that patients taking losartan need to stop taking the drug or switch to another ARB, American Heart Association spokesman Clyde W. Yancy, MD, tells WebMD.

Yancy is chief of cardiology at Chicago’s Northwestern University Feinberg School of Medicine.

“The bottom line is this should not change clinical practice,” he says. “We have seen nothing that raises concerns that this drug or any other angiotensin receptor blocker causes harm.”

Manufacturer: ‘More Study Needed’

In several previous studies examining ARBs in the treatment of heart failure, benefits were limited to patients with compromised heart function, as evidence by reduced left ventricular ejection fraction (LVEF).

Today on WebMD

Compressed heart
Salt Shockers
Inside A Heart Attack
lowering blood pressure

Mechanical Heart
Omega 3 Overview Slideshow
Atrial Fibrillation Guide
Simple Steps to Lower Cholesterol

Compressed heart
FAQ Heart Failure
Cholesterol Confusion
Health Check
Resolved To Quit Smoking